Preeclampsia Diagnostics Market Growth Potential and Emerging Opportunities 2034

The global preeclampsia diagnostics market trends in 2026 is witnessing steady development as healthcare providers increasingly focus on the early identification and monitoring of hypertensive disorders during pregnancy. Preeclampsia is a rapidly progressive pregnancy-related disorder characterized by elevated blood pressure and excessive protein in the urine. Early diagnosis is important because untreated preeclampsia can lead to serious complications, including preterm birth, seizures or eclampsia, organ failure, and death. The increasing prevalence of the condition and the growing emphasis on maternal and newborn health are contributing to demand for advanced diagnostic solutions.

According to Fortune Business Insights, the global preeclampsia diagnostics market size was valued at USD 1.13 billion in 2025. The market is projected to grow from USD 1.15 billion in 2026 to USD 1.46 billion by 2034, exhibiting a CAGR of 3.04% during the forecast period. North America dominated the preeclampsia diagnostics market with a market share of 37.60% in 2025. The market is being supported by technological advancements, increasing awareness, improved diagnostic capabilities, and the development of innovative tests for identifying biomarkers associated with preeclampsia.

Preeclampsia diagnostics include tests and diagnostic products used to identify the condition and assess the risk of its development during pregnancy. The market covers blood tests, urine analysis, instruments, and consumables used across hospitals, specialty clinics, diagnostic centers, and other healthcare settings. Blood-based diagnostic approaches have gained considerable attention because biomarkers can assist healthcare professionals in detecting and predicting preeclampsia.

Market Drivers & Restraints:

Increasing Prevalence of Preeclampsia

The rising number of women affected by preeclampsia is creating demand for early screening and diagnostic solutions. Fortune Business Insights notes that the incidence of preeclampsia ranges between 2% and 10% of pregnancies globally, with higher rates reported in developing countries. Increasing awareness among healthcare providers and pregnant women is supporting demand for early detection.

Development of Innovative Diagnostic Products

The growing focus on innovative diagnostic products is another important market growth factor. Point-of-care testing can support earlier diagnosis and may help avoid unnecessary hospital admissions. Advancements in biomarker testing and the development of tests designed to predict preeclampsia are creating additional opportunities for market participants. In July 2023, the U.S. FDA approved a blood test developed by Thermo Fisher Scientific Inc. for predicting preeclampsia in pregnant women between the 23rd and 35th weeks of pregnancy.

Limited Awareness in Developing Regions

Limited awareness of preeclampsia and its symptoms remains a restraint on market expansion. A single elevated blood pressure measurement does not effectively diagnose the condition, while some pregnant women may remain unaware of its severity until later stages. The limited availability of diagnostic products in certain regions, combined with inadequate awareness, can restrict adoption.

Market Competitive Landscape:

The competitive landscape includes established companies with strong product offerings and a focus on developing advanced and cost-effective diagnostic kits. F. Hoffmann-La Roche Ltd., PerkinElmer Inc., and DRG INSTRUMENTS GMBH are identified by Fortune Business Insights as leading players in the market. Companies are focusing on research and development activities, product launches, distribution improvements, strategic collaborations, and partnerships to strengthen their market presence.

Top Companies In The Market

• F. Hoffmann-La Roche Ltd (Switzerland)

• PerkinElmer Inc. (U.S.)

• DRG INSTRUMENTS GMBH (Germany)

• Thermo Fisher Scientific Inc. (U.S.)

• Diabetomics, Inc. (U.S.)

• Metabolomic Diagnostics Ltd. (Ireland)

• Sera Prognostics (U.S.)

• Siemens Healthineers AG (Germany)

• Bayer AG (Germany)

Market Segments:

By Test Type (Blood Tests and Urine Analysis)

By Product (Instruments and Consumables)

By End-user (Hospitals, Specialty Clinics, Diagnostic Centers, and Others)

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/preeclampsia-diagnostics-market-101519 

Market Regional Insights:

North America

North America dominated the market with a 37.60% share in 2025. The regional market was valued at USD 0.42 billion in 2025 and is projected to reach USD 0.43 billion in 2026. Advanced diagnostic technologies, healthcare spending, and growing awareness among healthcare providers and patients are supporting regional growth. The U.S. market is projected to reach USD 0.40 billion in 2026.

Europe

Europe accounted for USD 0.29 billion in 2025, representing 25.48% of the global market. The market is projected to remain at USD 0.29 billion in 2026. The region is supported by a large patient population affected by hypertensive disorders during pregnancy and increasing government approvals for diagnostic solutions. The U.K. market is projected to reach USD 0.05 billion and Germany USD 0.08 billion in 2026.

Asia Pacific

Asia Pacific represented USD 0.34 billion in 2025, accounting for 30.41% of the global market, and is projected to reach USD 0.35 billion in 2026. Rising pregnancy rates, increasing awareness, a growing population, and increasing use of fertility treatments are contributing to regional expansion. Japan, China, and India are projected to reach USD 0.08 billion, USD 0.12 billion, and USD 0.06 billion, respectively, in 2026.

Future Market Scope:

The future of the preeclampsia diagnostics market is closely connected with the development of faster, accessible, and technologically advanced diagnostic solutions. Increasing research into biomarkers, genomics, artificial intelligence, machine learning, and other diagnostic technologies is expected to support innovation. Strategic collaborations among diagnostic companies and research organizations may further encourage the development of advanced testing solutions.

Explore Japan’s Market Opportunities - Latest -Preeclampsia Diagnostics Market- Insights